Clinical Trials Browser

Prostatic Neoplasms

Prostatic Neoplasms

Biochemically Recurrent Prostate Cancer

Hypertension, Kidney Diseases, Prostatic Neoplasms, Primary Dysautonomias

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Metastatic Castration-resistant Prostate Cancer

Prostatic Neoplasms

Adenocarcinoma of the Prostate

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Metastatic Hormone Sensitive Prostate Cancer

Prostatic Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body

Prostatic Neoplasms

Breast Neoplasms

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

Metastatic Castration Resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant

Prostatic Neoplasms

Prostatic Neoplasms, Castration-Resistant

Neoplasm Metastasis, Prostatic Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Neoplasm Metastasis, Prostatic Neoplasms

Metastatic Castration Resistant Prostate Cancer

Breast Neoplasms

Recurrent Endometrial Endometrioid Adenocarcinoma

Metastatic Castration Resistant Prostate Cancer

Breast Neoplasms

Prostatic Neoplasms

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

Prostatic Neoplasms

Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Metastatic Castration Resistant Prostate Cancer

Breast Neoplasms, Triple Negative Breast Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Clinical Trials

Radium-223 in Combination With Enzalutamide

Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

ARAMON

ARCH

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

PROSPER

CheckMate 9KD

FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

Testosterone Therapy in Castration Resistant Prostate Cancer

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy

An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants

ARCHES

ARROW

KEYNOTE-991

Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Study to Evaluate CCS1477 in Advanced Tumours

TRITON3

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer

BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)

Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer

KEYLYNK-010

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

ZZ-First

Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer

ODENZA

PRESIDE

A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy

A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer

A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer

Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer

A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients

Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer

A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100

UPWARD

A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer

ENACT

A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients

A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer

Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.

A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics

Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer

Addition of Opaganib to Androgen Antagonists in Patients With mCRPC

Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy